ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
130.568,37
-0,38%
S&P 500
5.718,57
0,28%
US Dollar vs BRL
5,51392
-0,43%
Bitcoin
63.046,04
-0,44%
Brent Oil
73,795
0,08%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Precigen Inc (PGEN)

  7. Precigen Inc (PGEN) Notícias

PGEN

Precigen (PGEN)

Precigen Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PGEN
DataHoraFonteTítuloCódigoCompanhia
16/09/202417:30PR Newswire (US)Precigen to Participate in the 2024 Cantor Global Healthcare ConferenceNASDAQ:PGENPrecigen Inc
30/08/202418:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PGENPrecigen Inc
14/08/202417:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PGENPrecigen Inc
14/08/202417:05PR Newswire (US)Precigen Reports Second Quarter and First Half 2024 Financial Results and Business UpdatesNASDAQ:PGENPrecigen Inc
13/08/202418:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PGENPrecigen Inc
09/08/202409:00PR Newswire (US)Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14thNASDAQ:PGENPrecigen Inc
08/08/202417:19Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PGENPrecigen Inc
07/08/202422:30PR Newswire (US)Precigen Announces Pricing of $30.0 Million Public Offering of Common StockNASDAQ:PGENPrecigen Inc
06/08/202417:04PR Newswire (US)Precigen Announces Proposed $30 Million Public Offering of Common StockNASDAQ:PGENPrecigen Inc
06/08/202417:01PR Newswire (US)Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy LaunchNASDAQ:PGENPrecigen Inc
24/07/202418:20Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PGENPrecigen Inc
23/07/202409:01PR Newswire (US)Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy LaunchNASDAQ:PGENPrecigen Inc
03/06/202410:30PR Newswire (US)Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete ResponseNASDAQ:PGENPrecigen Inc
28/05/202417:48Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:PGENPrecigen Inc
28/05/202417:44Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PGENPrecigen Inc
23/05/202418:00PR Newswire (US)Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual MeetingNASDAQ:PGENPrecigen Inc
14/05/202417:05PR Newswire (US)Precigen Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:PGENPrecigen Inc
08/05/202417:05PR Newswire (US)Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual MeetingNASDAQ:PGENPrecigen Inc
24/04/202411:20PR Newswire (US)Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual MeetingNASDAQ:PGENPrecigen Inc
24/04/202410:00PR Newswire (US)Actym Therapeutics Appoints Thomas Smart as CEONASDAQ:PGENPrecigen Inc
28/03/202417:05PR Newswire (US)Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11thNASDAQ:PGENPrecigen Inc
19/03/202417:05PR Newswire (US)Precigen Reports Full Year 2023 Financial Results and Business UpdatesNASDAQ:PGENPrecigen Inc
19/03/202408:27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:PGENPrecigen Inc
12/03/202417:05PR Newswire (US)Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory PapillomatosisNASDAQ:PGENPrecigen Inc
05/03/202418:05PR Newswire (US)Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19thNASDAQ:PGENPrecigen Inc
27/02/202415:48Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PGENPrecigen Inc
14/02/202418:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PGENPrecigen Inc
06/02/202418:05PR Newswire (US)Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:PGENPrecigen Inc
18/01/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PGENPrecigen Inc
16/01/202410:05PR Newswire (US)Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European CommissionNASDAQ:PGENPrecigen Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:PGEN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
IFCM3
Infracommerce Caxaas ON
BOV
AZUL4
AZUL PN
BOV
PDGR3
PDG REALT ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados